Dermatology

>

Latest News

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

June 27th 2025

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis | Image credit: Weill Cornell Medicine
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis

June 25th 2025

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics.
FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

June 20th 2025

FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis | Image Credit: Contemporary Pediatrics
FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis

June 16th 2025

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

June 13th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.